Gene expression of androgen metabolising enzymes in benign prostatic hyperplasia

Klinichescheskaya Laboratornaya Diagnostika

Volumn , Issue 10, 2013, Pages 16-18

  Otpuschennikov, A A ^a   Khvostova, E P ^a   Krasilnikov, C E ^a   Gulyaeva, L F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84898447624     PISSN: 08692084     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Almeida J., Conley A. J., Mathewson L., Ball B. A. Expression of steroidogenic enzymes during equine testicular development. Reproduction. 2011;141(6):841-8.
2. Basu S., Tindall D. Androgen action in prostate cancer. Horm. Cancer. 2010;1(5):223-8.
3. Chang B., Zheng S., Hawkins G., Isaacs S., Wiley K., Turner A. et al. Joint Effect of HSD3B1 and HSD3B2 Genes Is Associated with Hereditary and Sporadic Prostate Cancer Susceptibility. Cancer Res. 2002;62(6):1784-9.
4. Cai C., Balk S. Intratumoral Androgen Biosynthesis in Prostate Cancer Pathogenesis and Response to Therapy. Endocr. Relat. Cancer. 2011;18(5):175-82.
5. Chumsri S., Howes T., Bao T., Sabnis G., Brodie A. Aromatase, Aromatase Inhibitors, and Breast Cancer. J. Steroid Biochem. Mol. Biol. 2011;125:13-22.
6. Hu D., Mackenzie P. Forkhead box protein Al regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells. Drug. Metab. Dispos. 2010;38(12):2105-9.
7. Ho S. M., Lee M. T., Lam H. M., Leung Y. K. Estrogens and prostate cancer: etiology, mediators, prevention, and management. Endocrinol. Metab. Clin. North. Am. 2011;40(3):591-614.
8. Ji Q., Chang L., Stanczyk F. Z., Ookhtens M., Sherrod A., Stolz A. Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKRIC2 as a pre-receptor regulator of androgen receptor signalling. Cancer Res. 2007;67(3):1361-9.
9. Li J., Ding Z, Wang Z, Lu J., Maity S., Navone N., Logothetis C., Mills G. Androgen regulation of 5a-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS. One. 2011;6(12):28840.
10. Montgomery R., Mostaghel E., Vessella R., Hess D., Kalhorn T., Higano C. et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447-54.
11. Penning T. M. New frontiers in androgen biosynthesis and metabolism. Cur. Opin. Endocrinol. Diabetes Obesit. 2010;17:233-9.
12. Pfeiffer M. J., Sniit F. P., Sedelaar J. P., Schalken J. A. Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol. Med. 2011;17(7-8):657-64.
13. Parsons K. J. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr. Bladder Dysfunct. Rep. 2010;5:212-8.
14. Rotinen M., Celay J., Alonso M., Arrazola A., Encio I., Villar J. Estradiol induces type 8 17beta-hydroxysteroid dehydrogenase expression: crosstalk between estrogen receptor alpha and C/EBPbeta. J. Endocrinol. 2009;200(1):85-92.
15. Senggunprai L., Yoshinari K., Yamazoe Y. Selective role of sulfotransferase 2A1 (SULT2A1) in the N-sulfoconjugation of quinolone drugs in humans. Drug. Metab. Dispos. 2009;37(8):1711-7.
16. Shiota M., Yokomizo A., Naito S. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. Mol. Endocrinol. 2011;47(1):25-41.
17. Voucher L., Paduch D. A., Jichlinski P. Testosterone and prostate. Med. Suisse. 2011;7(320):2399-400.